10q10k10q10k.net
RAPT Therapeutics, Inc.

RAPT Therapeutics, Inc.RAPTEarnings & Financial Report

Nasdaq · pharmaceutical industry

Horizon Therapeutics plc was a biopharmaceutical company focused on researching, developing, and commercializing medicines that address critical needs for people impacted by rare and rheumatic diseases. Horizon primarily markets products in the United States, which represented 97% of Horizon's 2019 worldwide sales. Amgen acquired the company in October 2023.

RAPT Q3 2023 Key Financial Metrics

Revenue

$0

Gross Profit

N/A

Operating Profit

$-33.9M

Net Profit

$-31.4M

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

YoY Growth

N/A

EPS

$-0.82

RAPT Therapeutics, Inc. Q3 2023 Financial Summary

RAPT Therapeutics, Inc. reported revenue of $0 for Q3 2023, with a net profit of $-31.4M (N/A margin). Cost of goods sold was N/A, operating expenses totaled N/A.

Key Financial Metrics

Total Revenue$0
Net Profit$-31.4M
Gross MarginN/A
Operating MarginN/A
Report PeriodQ3 2023

RAPT Therapeutics, Inc. Annual Revenue by Year

RAPT Therapeutics, Inc. annual revenue history includes year-by-year totals (for example, 2022 revenue was $1.5M).

YearAnnual Revenue
2022$1.5M

Income Statement

Q1 2022Q2 2022Q3 2022Q4 2022Q2 2023Q3 2023
Revenue$641000$886000$0$0$0$0
YoY Growth-47.5%2.0%N/AN/AN/AN/A

Balance Sheet

Q1 2022Q2 2022Q3 2022Q4 2022Q2 2023Q3 2023
Assets$187.5M$222.0M$209.5M$266.2M$220.8M$199.7M
Liabilities$19.7M$19.9M$20.2M$21.0M$21.1M$26.9M
Equity$167.8M$202.1M$189.3M$245.2M$199.7M$172.8M

Cash Flow

Q1 2022Q2 2022Q3 2022Q4 2022Q2 2023Q3 2023
Operating CF$-15.6M$-15.2M$-17.1M$-22.8M$-28.8M$-21.9M